Patents by Inventor James W. Gillespie

James W. Gillespie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230338462
    Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.
    Type: Application
    Filed: May 2, 2023
    Publication date: October 26, 2023
    Inventors: Tatiana I. SAMOYLOVA, Alexandre M. SAMOYLOV, Kenny V. BROCK, Anna M. COCHRAN, James W. GILLESPIE
  • Patent number: 11666624
    Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: June 6, 2023
    Assignees: Auburn University, Edward Via College of Osteopathic Medicine—Auburn
    Inventors: Tatiana I. Samoylova, Alexandre M. Samoylov, Kenny V. Brock, Anna M. Cochran, James W. Gillespie
  • Publication number: 20210085750
    Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 25, 2021
    Applicants: Auburn University, Edward Via College of Osteopathic Medicine - Auburn
    Inventors: Tatiana I. SAMOYLOVA, Alexandre M. SAMOYLOV, Kenny V. Brock, Anna M. Cochran, James W. Gillespie
  • Patent number: 9226972
    Abstract: Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of genes in target cells.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: January 5, 2016
    Assignee: Auburn University
    Inventors: Valery A. Petrenko, Deepa Bedi, Olusegun A. Fagbohun, James W. Gillespie
  • Publication number: 20130202679
    Abstract: Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of genes in target cells.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 8, 2013
    Applicant: AUBURN UNIVERSITY
    Inventors: Valery A. Petrenko, Deepa Bedi, Olusegun A. Fagbohun, James W. Gillespie